DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
+3.14%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$2.82B
AUM Growth
+$2.82B
(+11%)
Cap. Flow
+$167M
Cap. Flow
% of AUM
5.92%
Top 10 Holdings %
Top 10 Hldgs %
31.06%
Holding
130
New
28
Increased
28
Reduced
22
Closed
14
Top Buys
| 1 |
Q32 Bio
QTTB
|
$97.7M |
| 2 |
Centene
CNC
|
$62.8M |
| 3 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
$41.3M |
| 4 |
CVS Health
CVS
|
$34.2M |
| 5 |
GSK
GSK
|
$31.6M |
Top Sells
| 1 |
DexCom
DXCM
|
$65.6M |
| 2 |
Glaukos
GKOS
|
$52.4M |
| 3 |
Insulet
PODD
|
$46.3M |
| 4 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
$35.8M |
| 5 |
McKesson
MCK
|
$34.5M |
Sector Composition
| 1 | Healthcare | 76.69% |
| 2 | Financials | 1.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MNK
1
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $125M | 4.33% | 8,621,383 +2,855,383 | +50% | +$41.3M |
|
2
Viatris
VTRS
$12.3B
| $105M | 3.63% | 2,548,111 +44,500 | +2% | +$1.83M |
|
|
3
Q32 Bio
QTTB
$20.9M
| $97.7M | 3.39% | +5,227,035 | New | +$97.7M |
|
|
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $93.9M | 3.25% | 6,609,894 +268,000 | +4% | +$3.81M |
|
|
AVXS
5
DELISTED
AveXis, Inc. Common Stock
AVXS
| $93.4M | 3.24% | 755,798 | – | – |
|
6
AnaptysBio
ANAB
$569M
| $82.7M | 2.86% | 794,338 -18,146 | -2% | -$1.89M |
|
|
DBVT
7
DBV Technologies
DBVT
$264M
| $66.9M | 2.32% | 2,900,000 +794,820 | +38% | +$18.3M |
|
|
8
Centene
CNC
$14.3B
| $62.8M | 2.18% | +588,000 | New | +$62.8M |
|
|
MYOK
9
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $52.2M | 1.81% | 1,068,680 +68,000 | +7% | +$3.32M |
|
|
10
Glaukos
GKOS
$5.5B
| $50.7M | 1.76% | 1,643,031 -1,700,014 | -51% | -$52.4M |
|
|
11
DexCom
DXCM
$29.5B
| $48.1M | 1.67% | 649,000 -885,211 | -58% | -$65.6M |
|
12
Aclaris Therapeutics
ACRS
$209M
| $48.1M | 1.67% | 2,745,705 +512,289 | +23% | +$8.98M |
|
|
LCI
13
DELISTED
Lannett Company, Inc.
LCI
| $44M | 1.52% | 2,741,077 +23,790 | +0.9% | +$382K |
|
14
Elevance Health
ELV
$71.8B
| $42M | 1.45% | 191,000 +61,000 | +47% | +$13.4M |
|
|
BOLD
15
DELISTED
Audentes Therapeutics, Inc
BOLD
| $41.6M | 1.44% | 1,384,470 +193,954 | +16% | +$5.83M |
|
16
Editas Medicine
EDIT
$231M
| $38.4M | 1.33% | 1,158,841 -550,559 | -32% | -$18.3M |
|
17
BioCryst Pharmaceuticals
BCRX
$1.74B
| $35.1M | 1.22% | 7,366,460 +153,067 | +2% | +$730K |
|
|
BPMC
18
DELISTED
Blueprint Medicines
BPMC
| $34.8M | 1.2% | 378,950 -17,050 | -4% | -$1.56M |
|
|
19
CVS Health
CVS
$92.8B
| $34.2M | 1.19% | +550,000 | New | +$34.2M |
|
|
XENT
20
DELISTED
Intersect ENT, Inc
XENT
| $32.7M | 1.13% | 832,500 -635,841 | -43% | -$25M |
|
21
DaVita
DVA
$9.85B
| $32.1M | 1.11% | 486,427 +61,427 | +14% | +$4.05M |
|
22
Select Medical
SEM
$1.61B
| $32.1M | 1.11% | 1,858,000 | – | – |
|
|
23
GSK
GSK
$79.9B
| $31.6M | 1.1% | +810,000 | New | +$31.6M |
|
24
Ascendis Pharma
ASND
$11.8B
| $31.6M | 1.09% | 482,467 -306,533 | -39% | -$20M |
|
25
Universal Health Services
UHS
$11.6B
| $31M | 1.07% | 262,000 +130,000 | +98% | +$15.4M |
|